title: Limiting access to letrozole--is it justified?
abstract: Letrozole is an effective drug for ovulation induction and superovulation. Limiting its access is a disservice to our infertile patients and to the advancement in ovulation-related research.
authors.affiliation: Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada. togas.tulandi@mcgill.ca
authors.forename: Togas
authors.initials: T
authors.lastname: Tulandi
authors.forename: Alan H
authors.initials: AH
authors.lastname: DeCherney
mesh_terms: D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000600:supply & distribution*; D005260:Female; D006330:Heart Defects, Congenital / Q000139:chemically induced*; D006801:Humans; D007231:Infant, Newborn; D007247:Infertility, Female / Q000188:drug therapy*; D000077289:Letrozole; D009570:Nitriles / Q000009:adverse effects* / Q000627:therapeutic use; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole